Investing Insights Gain From the Weight-Loss Trend With These Stocks
Everyone’s been talking about the drug semaglutide, used to treat Type 2 diabetes. It’s marketed under the brand names Ozempic, Wegovy, and now, Mounjaro. Are any of the drugmakers a buy?
Salesforce’s Successful Quarter
HP is Having Problems
Macy’s Misses the Mark
Diabetes Drugs Take Over
Biotech Frontrunners
Why is Pfizer Underperforming?
Semaglutide Risks
Biotech Stock Picks
What Higher Yields Mean for Retired ‘Bucket’ Investors
Read about topics from this episode.
Salesforce Earnings: Margins Shine As New Signs of Pressure Remove Some Luster
HP Earnings: Sales Remain Soft, Although Improvement Is on the Horizon; Shares Fairly Valued
Macy’s Earnings: Lowered Outlook on Waning Spending Overshadows Positives; Shares Undervalued
Novo Nordisk and Eli Lilly Lead Potential $60 Billion Obesity Drug Market; Valuations Look Rich
Obesity Drug Stocks: Time to Buy?
What to watch from Morningstar.
Double Trouble: How the Dot-Com and Tech Bubbles Compare
What to Do as Recession Fears Grip Investors
Just Where’s the U.S. Economy Headed?
Active ETFs Take Off –– 3 Ideas for Investors
Read what our team is writing:
Follow us on social media.
Ruth Saldanha on Twitter: @karishmaruth
Facebook: https://www.facebook.com/MorningstarInc/
Twitter: https://twitter.com/MorningstarInc
Instagram: https://www.instagram.com/morningstar...
LinkedIn: https://www.linkedin.com/company/5161/